BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Enbrel (etanercept) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Enbrel (etanercept)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05950724-94@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Enbrel (etanercept): Phase 1 readout est. (NCT05950724)
DESCRIPTION:Enbrel (etanercept)\, phase 1.\nStudy: RENAL: TNF-alpha Inhibit
 or for Improving Renal Dysfunction and Primary Graft Dysfunction After Lun
 g Transplant\nEstimated primary completion: December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/etanercept#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05950724
URL:https://assetmemo.bio/drug/etanercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04066348-94@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Enbrel (etanercept): Phase 2 readout est. (NCT04066348)
DESCRIPTION:Enbrel (etanercept)\, phase 2.\nStudy: TNF-α Treatment of Blas
 t-Induced Tinnitus\nEstimated primary completion: December 2026. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/etanercept#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04066348
URL:https://assetmemo.bio/drug/etanercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06707194-94@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Enbrel (etanercept): Phase 4 readout est. (NCT06707194)
DESCRIPTION:Enbrel (etanercept)\, phase 4.\nStudy: Effect and Safety of Ben
 zathine Penicillin Combined With Etanercept on Spondyloarthritis\nEstimate
 d primary completion: 1 March 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/etanercept#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06707194
URL:https://assetmemo.bio/drug/etanercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07184853-94@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20270925
DTEND;VALUE=DATE:20270926
SUMMARY:Enbrel (etanercept): Phase na readout est. (NCT07184853)
DESCRIPTION:Enbrel (etanercept)\, phase na.\nStudy: Ruxolitinib Plus Etaner
 cept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD\nEstimated pr
 imary completion: 25 September 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/etanercept#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07184853
URL:https://assetmemo.bio/drug/etanercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03294954-94@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Enbrel (etanercept): Phase 1 readout est. (NCT03294954)
DESCRIPTION:Enbrel (etanercept)\, phase 1.\nStudy: GD2 Specific CAR and Int
 erleukin-15 Expressing Autologous NKT Cells to Treat Children With Neurobl
 astoma\nEstimated primary completion: December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/etanercept#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT03294954
URL:https://assetmemo.bio/drug/etanercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07138898-94@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Enbrel (etanercept): Phase 2 readout est. (NCT07138898)
DESCRIPTION:Enbrel (etanercept)\, phase 2.\nStudy: Immunosuppressant Manage
 ment in Rheumatology Patients Undergoing Elective Total Shoulder Arthropla
 sty\nEstimated primary completion: January 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/etanercept#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07138898
URL:https://assetmemo.bio/drug/etanercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03414502-94@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Enbrel (etanercept): Phase 3 readout est. (NCT03414502)
DESCRIPTION:Enbrel (etanercept)\, phase 3\, Rheumatoid Arthritis.\nStudy: T
 reatment of Rheumatoid Arthritis With DMARDs: Predictors of Response\nEsti
 mated primary completion: March 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/etanercept#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT03414502
URL:https://assetmemo.bio/drug/etanercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06585384-94@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Enbrel (etanercept): Phase 1 readout est. (NCT06585384)
DESCRIPTION:Enbrel (etanercept)\, phase 1.\nStudy: Safety of a Strategy Com
 bining Etanercept Administration With Repeated Contrast Ultrasound in Pati
 ents With Alzheimer's Disease\nEstimated primary completion: June 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/etanercept#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06585384
URL:https://assetmemo.bio/drug/etanercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06011889-94@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20281018
DTEND;VALUE=DATE:20281019
SUMMARY:Enbrel (etanercept): Phase 2/3 readout est. (NCT06011889)
DESCRIPTION:Enbrel (etanercept)\, phase 2/3.\nStudy: Study of the Efficacy 
 and Safety of Etanercept Treatment in Patients With SAPHO Syndrome\nEstima
 ted primary completion: 18 October 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/etanercept#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06011889
URL:https://assetmemo.bio/drug/etanercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07904780-94@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20291111
DTEND;VALUE=DATE:20291112
SUMMARY:Enbrel (etanercept): Phase 4 readout est. (NCT07904780)
DESCRIPTION:Enbrel (etanercept)\, phase 4.\nStudy: Withdrawal Versus Contin
 ued TNF Inhibitor Monotherapy Treatment in Children With Inactive Juvenile
  Idiopathic Arthritis\nEstimated primary completion: 11 November 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/etanercept#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07904780
URL:https://assetmemo.bio/drug/etanercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07352566-94@assetmemo.bio
DTSTAMP:20261121T005624Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Enbrel (etanercept): Phase 4 readout est. (NCT07352566)
DESCRIPTION:Enbrel (etanercept)\, phase 4\, Psoriasis.\nStudy: Utilization 
 of a Microdevice for Psoriasis and Atopic Dermatitis\nEstimated primary co
 mpletion: 1 June 2030. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/etanercept#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07352566
URL:https://assetmemo.bio/drug/etanercept#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
